Overview

Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis

Status:
Completed
Trial end date:
2018-05-04
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, double-dummy, active-controlled, dose-finding study to compare the efficacy, safety and tolerability of oral SCY-078 versus oral fluconazole in adult female subjects 18 years and older with moderate to severe Acute Vulvovaginal Candidiasis (AVVC). Approximately 180 eligible subjects (30 subjects per treatment group) will be enrolled and randomized into the study.
Phase:
Phase 2
Details
Lead Sponsor:
Scynexis, Inc.
Treatments:
Fluconazole
Ibrexafungerp